68Ga-exendin-4(68Ga-exendin-4) - _专利_临床

概要

基本信息

药物类型

诊断用放射药物

别名-

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段-

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 68Ga-exendin-4 相关的临床试验

NCT05662189 / RecruitingN/AIIT

Assessment of Pancreatic Beta Cell Mass and Function With the Aid of Positron Emission Tomography Imaging in Human Diabetes Mellitus

The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.

开始日期2022-03-15

申办/合作机构

Azienda Ospedaliero-Universitaria di Parma

[+1]

100 项与 68Ga-exendin-4 相关的临床结果

登录后查看更多信息

100 项与 68Ga-exendin-4 相关的转化医学

登录后查看更多信息

100 项与 68Ga-exendin-4 相关的专利（医药）

登录后查看更多信息

7

项与 68Ga-exendin-4 相关的文献（医药）

2025-01-01·CLINICAL NUCLEAR MEDICINE

Glucagon-Like Peptide-1 Receptor–Targeted PET/CT With 68Ga-HBED-CC-Exendin-4 in Localizing Insulinoma

Article

作者: Wang, Rongxi ; Zhu, Lin ; Pan, Qingqing ; Zhu, Zhaohui ; Wang, Guochang ; Ma, Heng ; Hong, Haiyan ; Wang, Jiarou ; Li, Linlin ; Chen, Jingci ; Luo, Yaping ; Kung, Hank F. ; Jin, Wenbin

Purpose:

Modifying glucagon-like peptide-1 receptor (GLP-1R)–targeted PET agent to achieve faster renal clearance and preserved high affinity to GLP-1R is clinically relevant. The aim of this study is to assess the performance of a newly developed GLP-1R–targeted agent, 68Ga-HBED-CC-exendin-4 in localizing insulinoma, and its biodistribution, as compared with previously introduced 68Ga-NOTA-exendin-4.

Patients and Methods:

Nineteen patients with endogenous hyperinsulinemic hypoglycemia were enrolled and referred for 68Ga-HBED-CC-exendin-4 PET/CT and 68Ga-NOTA-exendin-4 PET/CT within 2 consecutive days. Diagnostic performance of the 2 tracers in localizing insulinoma was evaluated, and SUV of the lesion, normal pancreas background, kidneys, and bladder were measured.

Results:

68Ga-HBED-CC-exendin-4 and 68Ga-NOTA-exendin-4 PET/CT exhibited an equivalent efficacy in detection rate (both sensitivity of 100%). Although SUVmax of the tumor in 68Ga-HBED-CC-exendin-4 was significantly lower than that in 68Ga-NOTA-exendin-4 (20.01 ± 9.41 vs 31.78 ± 15.46, P < 0.001) at 50 minutes postinjection, there was no significant difference in the tumor-to-background ratio between the 2 agents (8.61 ± 3.57 vs 8.18 ± 3.38, P = 0.326), and the lesions could be visible as early as 4 minutes postinjection for both agents in patients who underwent dynamic PET/CT. In addition, 68Ga-HBED-CC-exendin-4 exhibited approximately 30% decrease of the renal accumulation compared with 68Ga-NOTA-exendin-4 (SUVmean, 42.21 ± 5.79 vs 58.58 ± 10.06 at 50 minutes, P < 0.001).

Conclusions:

68Ga-HBED-CC-exendin-4 is an effective agent for localizing insulinoma showing similar detectability and tumor-to-background ratio compared with 68Ga-NOTA-exendin-4. Notably, 68Ga-HBED-CC-exendin-4 exhibits significantly lower renal uptake than 68Ga-NOTA-exendin-4, which might potentially benefit the detection of the tumors adjacent to the left kidneys.

2024-05-01·Indian journal of endocrinology and metabolism

Diagnostic Modalities, Management Considerations, and Outcomes of Insulinoma: A Case Series from a Tertiary Care Centre

Article

作者: Walia, Rama ; Das, Liza ; Behera, Arunanshu ; Shetty, Anirudh J. ; Rana, Surinder S. ; Jayant, Satyam S. ; Saikia, Uma N. ; Gulati, Ajay ; Dutta, Pinaki ; Bhadada, Sanjay K. ; Kumar, Rajender ; Singh, Harmandeep ; Mittal, Bhagwant R.

Abstract:

Introduction::

Insulinomas are rare, usually sporadic, and typically benign pancreatic neuroendocrine tumours. Pre-operative localization is challenging and evidence on comparative analysis of anatomic and scintigraphic modalities for pre-operative tumour localization is limited, even in contemporary series.

Methods::

The current study was designed to study the clinical features and management challenges of insulinomas managed at a tertiary care centre. Clinical features, diagnosis, imaging techniques, surgical procedures, and outcomes details were collated. Pre-operative imaging techniques (CT/MRI, nuclear scintigraphy) were compared with intraoperative and histopathological findings to assess their accuracy of localization.

Results::

Thirty-seven patients (15 females [42%]; median age 36 years [IQR 28–49]) were included in the study. In four patients (10.8%), the tumour occurred in the setting of multiple endocrine neoplasia type 1 (MEN 1) while the remaining were sporadic. The sensitivity of pre-operative localization was 61.5% (multiphasic CT), 66.6% (multiphasic MRI), 100% (68Ga Exendin-4 PET-CT), and 91.6% (EUS). Three patients with normal multiphasic CT had localization on 68Ga Exendin-4 PET-CT. The positive predictive value (PPV) of both Exendin-PET-CT and EUS was similar at 91.6% and 91.6%, respectively. All patients (except one with nesidioblastosis), who underwent enucleation or partial pancreatic resection, were cured.

Conclusion::

68Ga Exendin-4 PET-CT based is a non-invasive imaging modality that has high sensitivity and PPV and can be used as a first-line imaging modality. The overall prognosis of these tumours is good with high cure rates attained following surgical resection.

2023-07-01·Diabetes

Monitoring β-Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes.

Article

作者: de Galan, Bastiaan E ; Eriksson, Olof ; de Koning, Eelco J P ; van Koeverden, Sebastiaan ; Gotthardt, Martin ; van der Graaf, Marinette ; Brom, Maarten ; Jansen, Theodorus J P ; Velikyan, Irina ; Buitinga, Mijke ; Vantyghem, Marie-Christine ; Engelse, Marten A ; Nijhoff, Michiel F ; Pattou, François ; Beron, Amandine ; Boss, Marti

ARTICLE HIGHLIGHTS:

This clinical study researched the potential of radiolabeled exendin to follow the fate and survival of intrahepatic islet grafts. Is it feasible to quantitatively detect intrahepatic islet transplants with [68Ga]Ga-NODAGA-exendin-4 (68Ga-exendin) positron emission tomography (PET) imaging? Our study findings indicate that the imaging technique 68Ga-exendin PET can be used to monitor viable islet mass after intrahepatic islet transplantation in humans. Alongside functional measures, 68Ga-exendin PET imaging could significantly aid in the evaluation of strategies designed to improve islet engraftment, survival, and function.

100 项与 68Ga-exendin-4 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2023	N/A	先天性高胰岛素血症	-	68Ga-EXENDIN-4 PET-CT	醖範窪範廠簾鑰窪餘製(網淵壓鬱廠醖憲鏇鏇憲) = 憲憲鑰構網衊顧鹹醖蓋襯憲積構鑰窪窪廠餘鑰 (艱艱衊壓餘製顧築鹹淵 ) 更多	-	2023-08-28
SNMMI2017	N/A	胰岛素瘤	-	68Ga-exendin-4 PET/CT	蓋襯鬱廠鹹築獵窪網顧(構鏇艱齋膚糧壓衊鬱衊) = 鹹憲艱糧齋鬱鹽鬱築衊蓋築範鏇網鬱簾遞糧艱 (鏇齋糧顧窪製淵觸顧製 ) 更多	-	2017-05-24
SNMMI2015	N/A	胰岛素瘤	-	68Ga-NOTA-exendin-4 PET/CT	壓衊鏇壓構願夢鏇齋艱(憲鹽構鬱製衊餘壓鑰簾) = 製鑰齋襯簾選製齋鑰膚鹽壓獵窪選簾鑰襯築廠 (壓製憲鹹鬱選醖鏇膚糧 ) 更多	-	2015-05-15
SNMMI2015	N/A	胰岛素瘤	-	68 Ga-exendin-4 (99mTc-HTOC SPECT/CT)	壓衊鏇壓構願夢鏇齋艱(憲鹽構鬱製衊餘壓鑰簾) = 遞鹹蓋製鹽膚淵糧遞鑰鹽壓獵窪選簾鑰襯築廠 (壓製憲鹹鬱選醖鏇膚糧 )	-	2015-05-15